Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt

Allergic Rhinitis: later-stage trial registry

2 of 24 indexed Allergic Rhinitis trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #686 of 28,707 conditions by registered trial count.

24 US clinical trials · 2 currently recruiting · #686 of 28,707 conditions by registered trial count

Allergic Rhinitis: 24 US clinical trials tracked, 2 recruiting.

Allergic Rhinitis is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 2 of these trials.

Enrollment posture brief

Registry condition allergic-rhinitis

OPEN 2 | RECR 8% | LATE 13 | EARLY 6 | RANK #686 | SPON 2

Nearest open-share peer: Anorexia (8% recruiting · 12 trials)

Aplastic Anemia37.5%Behavior37.5%Bleeding29.2%Allergic Rhinitis (this)8%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Allergic Rhinitis

Allergic Rhinitis lists 2 open slots (8% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Allergic Rhinitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Allergic Rhinitis is recruiting below its size-band peers.

    2 of 24 indexed trials (8.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Allergic Rhinitis trials is spread across many organizations.

    Sanofi accounts for 2 of 24 trials (8.3%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Most Allergic Rhinitis trials plan to enrol fewer than 100 people.

    Median target enrolment is 59 among the 24 trials that report a genuine target (sentinel values excluded). 18 of those (75%) plan for fewer than 100 participants.

  4. Allergic Rhinitis research is mostly interventional.

    22 interventional and 2 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 33Phase 410

Open and recent trials

24 total, page 1 of 1

RECRUITING NA 96 participants

Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?

Northwell Health

NCT05287841

RECRUITING Phase 2 75 participants

Viral Mucosal Reprogramming

The University of Texas Medical Branch, Galveston

NCT05331170

ACTIVE NOT RECRUITING Phase 4 39 participants

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

House Ear Institute

NCT04815187

COMPLETED Phase 3 430 participants

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

Greer Laboratories

NCT00599872

COMPLETED Phase 3 405 participants

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

Meda Pharmaceuticals

NCT01794741

COMPLETED Phase 3 353 participants

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Regeneron Pharmaceuticals

NCT04709575

COMPLETED Phase 4 220 participants

Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

Sanofi

NCT00636870

COMPLETED Phase 2 103 participants

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

Regeneron Pharmaceuticals

NCT03558997

COMPLETED Phase 4 102 participants

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

Alcon Research

NCT00772304

COMPLETED Phase 4 98 participants

Comparability and Standardization of Controlled Allergen Challenge Facilities

Queen's University

NCT02543346

COMPLETED 74 participants

Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism

Children's Mercy Hospital Kansas City

NCT00362999

COMPLETED Phase 2 74 participants

A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT00604123

COMPLETED 59 participants

Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases

Boston Children's Hospital

NCT02831348

COMPLETED NA 54 participants

Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies

University of North Carolina, Chapel Hill

NCT00617110

COMPLETED Phase 4 42 participants

Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine

Sanofi

NCT00637585

COMPLETED Phase 4 40 participants

The Effect of Cetirizine on Bronchoconstriction

New York City Health and Hospitals Corporation

NCT03340740

COMPLETED Phase 4 30 participants

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Covis Pharma S.à.r.l.

NCT00458835

COMPLETED Phase 4 22 participants

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

West Penn Allegheny Health System

NCT01550471

COMPLETED Phase 1 22 participants

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

Immunomic Therapeutics

NCT02146781

COMPLETED Phase 4 22 participants

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

University of Chicago

NCT02402465

COMPLETED Phase 2 20 participants

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

University of Chicago

NCT00791102

COMPLETED NA 18 participants

The Effect of Omalizumab on Responses to Cat Allergen Challenge

Johns Hopkins University

NCT00604786

COMPLETED Phase 1 17 participants

Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash

Drexel University

NCT01647633

COMPLETED Phase 4 6 participants

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

University of California, Davis

NCT00367016

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 3
Phase 4 10

Named interventions

Most-linked intervention names on Allergic Rhinitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Fexofenadine Drug
2 trials
JNJ-17166864 Drug
1 trials
LAIV and diesel exhaust particles Other
1 trials
live attenuated influenza virus (LAIV) with clean air Other
1 trials
Nasal Allergen Challenge Procedure
1 trials
Fluticasone/Azelastine nasal spray Drug
1 trials
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection Biological
1 trials

US sites by state

Facility locations filed on Allergic Rhinitis trials. A trial with sites in several states counts in each.

Missouri 6 trials
Texas 5 trials
New Jersey 4 trials
Illinois 4 trials
California 4 trials
Pennsylvania 3 trials
New York 3 trials
Minnesota 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Allergic Rhinitis page

24 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Allergic Rhinitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Sanofi sponsors the most Allergic Rhinitis trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Allergic Rhinitis condition card totals 24 registered trials; most-linked intervention Placebo; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.